- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Kristi Rosa | Authors
Articles
Early Efficacy, Safety Noted With Lisaftoclax in First-in-Human CLL Trial
July 07, 2021
In a trial of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and other hematologic cancers, the BCL-2 inhibitor lisaftoclax demonstrated feasibility as a treated option in the relapsed or refractory setting.
Patients With R/R CLL Have Promising Efficacy Outcomes With Zanubrutinib
June 22, 2021
All patients with chronic lymphocytic leukemia who were treated with zanubrutinib in the relapsed/refractory setting showed impressive responses.
Maintenance Therapy Panitumumab Plus 5-FU/Leucovorin Improves Survival in RAS Wild-Type Metastatic CRC
June 08, 2021
Adding panitumumab to 5-FU and leucovorin significantly improved PFS compared with 5-FU/leucovorin alone as a maintenance therapy for patients with RAS wild-type metastatic CRC.
Sacituzumab Govitecan for Metastatic TNBC Retains Survival Advantage Over Chemotherapy
June 08, 2021
Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician's choice chemotherapy.
Novel CART-ddBCMA Leads to 100% Response Rate in First-in-Human Myeloma Trial
June 07, 2021
In a first-in-human study of patients with relapsed or refractory multiple myeloma, the autologous CAR T-cell therapy CART-bbBCMA led to at least a partial response in all treated patients.
Ribociclib Plus Fulvestrant Continued to Improve OS in Advanced, HR+ Breast Cancer, Regardless of Setting
June 05, 2021
Ribociclib (Kisqali) plus fulvestrant (Faslodex) maintained significantly improved overall survival (OS) rates after nearly 5 years of follow-up compared to fulvestrant alone in postmenopausal patients who had hormone receptor (HR)-postivie, HER2-negative advanced breast cancer.
Durable and Meaningful Efficacy Seen in Patritumab Deruxtecan for EGFR TKI–Resistant EGFR+ NSCLC
June 05, 2021
For heavily pretreated patients with EGFR-mutated NSCLC resistant to EGFR TKIs, patritumab deruxtecan induced clinically meaningful and durable efficacy.
PFS Boost Observed in Metastatic Nasopharyngeal Carcinoma Treated With Frontline Toripalimab/Chemotherapy Combo
June 03, 2021
Results of the phase 3 JUPITER-02 trial presented at ASCO 2021 support the use of toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.
Tislelizumab Plus Sitravatinib Demonstrates Antitumor Activity, Maintains Safety in Platinum-Resistant Epithelial Ovarian Cancer
April 14, 2021
For patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.
Zenocutuzumab Shows Ability to Inhibit NRG1 Fusion–Positive Tumors
April 14, 2021
Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.